Android app Apple app link

Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia

By Yahoo! Finance   |   1 month ago
Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia

Zai Lab's Phase III trial of KarXT for schizophrenia in China showed positive outcomes, meeting primary and secondary endpoints. The trial demonstrated the potential of KarXT as a new treatment option. Zai Lab plans to submit an NDA to NMPA by early 2025.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.